Popular Articles
Today Week Month Year


Ivermectin available over the counter in Tennessee
By News Editors // May 02, 2022

NASHVILLE, TN – Governor Bill Lee has signed SB 2188 that allows Ivermectin, an award-winning antiviral drug, to be available for the treatment of COVID-19 without a prescription in Tennessee. The state’s Senate overwhelmingly voted 66-20, and the House voted 22-6 in favor of the bill.

Brighteon.TV

(Article republished from TheDesertReview.com)

The bill states that a pharmacist can provide Ivermectin to a patient, who is 18 years of age or older, “pursuant to a valid collaborative pharmacy practice agreement containing a non-patient-specific prescriptive order and standardized procedures developed and executed by one or more authorized prescribers.”

That means that adults can explain their symptoms to the pharmacist, fill out a sheet listing any preexisting conditions and other medications they are taking, and the pharmacist can determine the right dosage.

Medical professionals such as Dr. Robert Malone, Dr. Ryan Cole, Dr. Richard Urso, Dr. Pierre Kory, Dr. John Little and many others worked diligently to educate Tennessee lawmakers about this effective drug.

The 2015 Nobel Prize in Physiology and Medicine was awarded to William C. Campbell and Satoshi Ömura for their discoveries leading to Ivermectin. Ivermectin is best known for its antiparasitic properties that can help prevent COVID-19 and is especially effectiveas early treatment. The drug also has antiviral and anti-inflammatory properties and studies have shown that ivermectin helps to lower the viral load by inhibiting replication. According to a June 2020 study published in the Antiviral Research Journal, a single dose of Ivermectin can kill 99.8 percent of the virus within 48 hours. A meta-analysis in the American Journal of Therapeutics showed the drug reduced infection by an average of 86 percent when used preventively.

In another study of 115 patients with COVID-19 who received a single dose of Ivermectin, none of them developed pneumonia or cardiovascular complications, while 11.4 percent of those in the control group did. Fewer Ivermectin patients developed respiratory distress, fewer required oxygen, antibiotics and intensive care. Ivermectin-treated patients tested negative in four days instead of 15 and stayed in the hospital nine days on average instead of 15.

Ivermectin has also been shown to speed recovery, in part by inhibiting inflammation and protecting against organ damage. Additionally, Ivermectin lowers the risk of hospitalizationand death. Furthermore, the drug prevents transmission of SARS-CoV-2 when taken before or after exposure.

Liberty Counsel Founder and Chairman Mat Staver said, “Cheap and effective drugs like Ivermectin are being denied to the public while pharmaceutical companies make money from COVID shots that are neither safe nor effective. Studies and personal testimonies have repeatedly shown the effectiveness of Ivermectin. The focus should always be about helping save lives rather than putting more money in the pockets of Big Pharma. All states should follow Tennessee’s lead.”

Read more at: TheDesertReview.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.